GB Patent

GB2381194A — Pharmaceutical formulations

Assigned to GW Pharma Ltd · Expires 2003-04-30 · 23y expired

What this patent protects

Pharmaceutical formulations for use in the administration of medicaments, in particular lipophilic medicaments, via mucosal surfaces. In particular the invention relates to formulations which, upon hydration, form an emulsion containing the lipophilic medicament which is capable …

USPTO Abstract

Pharmaceutical formulations for use in the administration of medicaments, in particular lipophilic medicaments, via mucosal surfaces. In particular the invention relates to formulations which, upon hydration, form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. Also outlined are:<BR> a cannabis-based pharmaceutical formulation comprising the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC) or the cannabinoids tetrahydrocannabinovarin (THCV) and cannabidivarin (CBDV);<BR> and the use of cannabidiol (CBD) to extend the shelf-life of a pharmaceutical product comprising at least one biologically active compound.

Drugs covered by this patent

Patent Metadata

Patent number
GB2381194A
Jurisdiction
GB
Classification
—
Expires
2003-04-30
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.